DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Polycystic Kidney Disease - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Polycystic Kidney Disease Overview
- Therapeutics Development
- Pipeline Products for Polycystic Kidney Disease - Overview
- Pipeline Products for Polycystic Kidney Disease - Comparative Analysis
- Polycystic Kidney Disease - Therapeutics under Development by Companies
- Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes
- Polycystic Kidney Disease Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Polycystic Kidney Disease - Products under Development by Companies
- Polycystic Kidney Disease - Products under Investigation by Universities/Institutes
- Polycystic Kidney Disease - Companies Involved in Therapeutics Development
- 3SBio Inc.
- Angion Biomedica Corp.
- DiscoveryBiomed, Inc.
- Endocyte, Inc.
- IC-MedTech, Inc.
- Ipsen S.A.
- Kadmon Corporation, LLC
- Metabolic Solutions Development Company, LLC
- NovaTarg Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Synta Pharmaceuticals Corp.
For more information visit http://www.researchandmarkets.com/research/nhrbwz/polycystic_kidney